Navigation Links
ICON Central Laboratories in Singapore Moves to New Facility to Meet Growing Demand
Date:6/26/2009

DUBLIN, June 26 /PRNewswire-FirstCall/ --

- Singapore Laboratory Testing Increases by 149% in Past Six Months

ICON plc (NASDAQ:ICLR: ISIN: IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has moved its Singapore central laboratory to a new, larger facility located at Loyang Way, Eastern Singapore. The new laboratory meets the growth in demand for ICON Central Laboratories' services in Singapore, which has increased by 149% over the past six months. The larger facility also enables ICON Central Laboratories to expand its test menu offerings in the region to include increased esoteric testing as well as flow cytometry, molecular diagnostics and biomarkers, to complement the services of ICON's other wholly-owned central laboratories in Europe, India and the United States.

"As ICON celebrates its tenth year of operation in Singapore, our move to a larger laboratory signals our continued commitment to the region," commented Bob Scott-Edwards, President, ICON Central Laboratories. "Singapore has become a regional hub for drug development in Asia-Pacific and we now have the capacity, the range of testing services and, above all, a highly experienced team of lab professionals to support the growth of clinical trials in the region."

ICON Central Laboratories Singapore supports all major therapeutic areas, including cardiovascular, oncology, endocrinology and metabolism, and virology. The laboratory serves as a regional hub for test samples from Australia, New Zealand, South Korea, Malaysia, Singapore, Taiwan, Japan, Thailand, Hong Kong, China and Indonesia. ICON Central Laboratories Singapore received CAP (College of American Pathologists) accreditation in March 2009, ensuring the highest standards of excellence in laboratory services.

About ICON Central Laboratories

ICON Central Laboratories, a division of ICON plc, provides full service, global central laboratory services from core facilities in New York, Dublin, Singapore and India, as well as through quality affiliate laboratories in China and Japan. An extensive test menu of safety, esoteric and custom-developed assays, including global flow cytometry, is complemented by dedicated, sponsor-specific project teams and a single, comprehensive database for each study as well as a user-friendly, web-based, secure remote data access system. ICON Central Laboratories also offers a unique service to manage and compile laboratory data when a client's study requires the use of local laboratories.

    ICON/ICLR-G

    For more information, visithttp://www.icolabs.com.

    US contact:
    Courtney Judd
    +1-212-445-8365

    UK contact:
    Erika Aalto
    +44(0)20-706-70-214


'/>"/>
SOURCE ICON plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition
2. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
3. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
4. Bio-Tech Medical Software, Inc. Biometrics Joins Forces with the University of Central Florida to Fight Diversion and Help Combat Prescription Narcotic Drug Abuse
5. Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia
6. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
7. ICON Opens Full Service Central Laboratory in India
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
10. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
11. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Band-LOK, LLC, ... announced today that two new patents have been allowed by the USPTO on ... Band-LOK, said, “We continue to explore additional clinically-relevant designs for both the implants ...
(Date:9/18/2017)... , a growing leader in Electronic Trial Master file solutions ... research organization, Multidisciplinary Association for Psychedelic Studies (MAPS). ... MAPS Public Benefit Corporation selects ... ... for the treatment of Posttraumatic Stress Disorder (PTSD). MAPS also reached ...
(Date:9/15/2017)... San Diego, CA (PRWEB) , ... September 15, ... ... manufacturer Grolltex, has recently closed what it calls an ‘Internal Seed B’ round ... of the company’s stock and was completed using a ‘SAFE’ documentation structure at ...
(Date:9/14/2017)... Frederick, Maryland (PRWEB) , ... ... ... today, proudly announces the launch of its CliniControl™ (CC) product portfolio, clinically-relevant ... manufacturing, accelerating clinical translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The ...
Breaking Biology Technology:
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):